Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Durability of Adherence in Self-Management of HIV (DASH)

21 lutego 2018 zaktualizowane przez: AIDS Clinical Trials Group
Adherence to highly active antiretroviral therapy (HAART) is critical to successful treatment of HIV. This study tested an intervention that helps people infected with HIV take all their medications when and how they were supposed to.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

People infected with HIV must take the regimen of highly active antiretroviral therapy (HAART) medications as prescribed to them, without missing doses, or they risk developing a resistant strain of the virus. Resistant strains of the virus do not respond to certain HAART regimens and are more dangerous for patients. Poor HAART adherence can lead to further HIV progression, more hospitalizations and opportunistic infections, and required use of second-line therapies. Interventions to increase adherence have had mixed success, with little data to support long-term effects and no one strategy emerging that provides consistent positive effects. The client adherence profiling and intervention tailoring (CAP-IT) program was first developed to increase adherence among people already on HAART with in-home nursing. This study modified CAP-IT to treat people newly on HAART and then tested whether this modified CAP-IT improved long-term HAART adherence.

This study included two stages. The first stage consisted of two focus groups, one made up of HIV care providers and professionals and the other made up of people infected with HIV who had started HAART within the last year. Each focus group met once, for approximately 2 hours, to determine what modifications would best adapt the CAP-IT program to HIV-infected people first starting HAART.

The second stage consisted of a randomized trial comparing the modified CAP-IT program to standard of care. Participation in this stage lasted for 72 weeks. Participants were randomly assigned to receive either standard care or the modified CAP-IT program in addition to standard care. The CAP-IT program involved two steps. The first was an assessment of factors relating to adherence, and the second was development of an individualized plan to address the deficits found.

Study visits were completed at entry, at Weeks 4 and 12, and then every 12 weeks for approximately 72 weeks. Assessments for the study included a questionnaire about health attitudes, a physical exam, counting of pills, and answering questions about taking medications.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

172

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Peru
      • Lima, Peru, 18 PE
        • Barranco CRS (11301)
  • Stany Zjednoczone
    • California
      • San Diego, California, Stany Zjednoczone, 92037
        • Ucsd, Avrc Crs

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Stage 1

    • HIV infected Individuals on Highly Active Antiretroviral Therapy (HAART):

      • HIV-1 infection
      • Initiated HAART within 1 year prior to study entry and remained on HAART for at least 30 consecutive days
      • Men and women who hade reached the legal age of majority in the country where they are being enrolled
      • Ability and willingness to provide informed consent
      • Willingness to discuss personal topics during an audio-taped group interview
      • Willingness to protect the confidentiality of other focus group participants

    • Health Care Providers and Professionals:

      • Healthcare providers or professionals (e.g., medical doctors [MDs], nurse practitioner [NPs], physician assistants [PAs], adherence counselors) recruited from outside of the local clinical research site (CRS) whose patient population included a majority of HIV-1 seropositive patients and who had recent experience managing ART-naive individuals starting HAART
      • Men and women who had reached the legal age of majority in the country where they are being enrolled
      • Willingness to discuss personal topics during an audio-taped group interview
      • Willingness to protect the confidentiality of other focus group participants and of the proceedings

  • Stage 2:

    • HIV-1 infection
    • Antiretroviral (ARV) treatment naive, but planning to initiate HAART within 7 days of study entry either in the context of an approved parent AIDS Clinical Trial Group (ACTG) clinical trial or in the context of primary HIV care at a University of California, San Diego (UCSD), USA or Asociacion Civil Impacta Salud Y Educaci (IMPACTA), Peru, CRS-affiliated site
    • HIV-1 RNA greater than 1,000 copies/mL obtained within 90 days prior to study entry by any laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent
    • CD4+/CD8+ count obtained within 90 days prior to study entry by any laboratory that has a CLIA certification or its equivalent
    • Men and women who had reached the legal age of majority in the country where they are being enrolled
    • Ability to follow instructions and complete surveys and questionnaires with minimal assistance

Exclusion Criteria:

  • Stage 1

    • HIV-1 Infected Individuals on HAART:

      • Failure to remain on HAART for at least 30 consecutive days
      • Diminished cognitive capacity that, in the opinion of the screening CRS clinician, would interfere with study participation
      • Participation in any prior focus group for study A5250

    • Health Care Providers and Professionals:

      • Health care providers and professionals who would be involved in administering standard of care (SOC) treatment and adherence counseling to Stage 2 participants randomized to the SOC arm or CRS investigators or health care providers and professionals directly involved in measuring adherence outcomes in Stage 2
      • Participation in any prior focus group for study A5250

  • Stage 2:

    • Potential participants who were, in the judgment of the research team, unable to complete the protocol
    • Potential participants who were starting a NNRTI-based regimen within 12 months after receiving single-dose NVP during pregnancy to prevent MTCT of HIV
    • Potential participants who were partners or close contacts of participants enrolled in Stage 2
    • Potential participants who were currently enrolled in an ACTG protocol utilizing or testing an adherence intervention

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: CAP-IT

Participants received the modified CAP-IT adherence intervention in addition to standard care.

Modified client adherence profiling and intervention tailoring (CAP-IT): Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
Behawioralne: CAP-IT
Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
Inne nazwy:
  • Client adherence profiling and intervention tailoring
Brak interwencji: Standard care
Participants received standard care.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Mean Self-reported Adherence Score (%) Over a One-month Recall
Ramy czasowe: At weeks 4, 12, 24, 36, and 48

The adherence self-report questionnaire captured adherence at an Antiretroviral Therapy (ART) regimen over a one-month recall (0-100): 0 means none of anti-HIV medications were taken, 100 means every single dose of anti-HIV medications were taken. The primary endpoint evaluated for each participant was the average self-reported adherence over a one-month recall across each of their study visit week 4, 12, 24, 36, and 48: missing values were ignored.

Note: This was a change to the primary endpoint as described in the study protocol. This was due to an update to ACTG Case Report Form (CRF) that captured self-report adherence. Since the data captured on this form captured adherence over a longer timeframe and allowed for more variability in response, it was anticipated this endpoint would provide greater power to assess treatment differences.
At weeks 4, 12, 24, 36, and 48

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Mean Self-reported Adherence Score Over a One-month Recall
Ramy czasowe: Weeks 4, 12, 24, 36, 48, 60, and 72
The mean of participant's average self-reported adherence score over a one-month recall across visit week 4, 12, 24, 36, 48, 60, and 72; missing values were ignored.
Weeks 4, 12, 24, 36, 48, 60, and 72
Kaplan-Meier Estimate of the Cumulative Probability of Time to Change of Initial Antiretroviral (ARV) Treatment Regimen for Any Reason by Week 48
Ramy czasowe: From study entry to week 48

The Kaplan-Meier estimate of the cumulative probability of initial antiretroviral (ARV) treatment regimen for any reason by week 48.

Time to ARV treatment regimen change was defined as first time to change in the drug class of participant's ART regimen for any reason from study entry. Participants completing the study without a change in the drug class of their ART regimen were censored at their last visit.
From study entry to week 48
Virologic Suppression
Ramy czasowe: At week 24, 48, 72
Virologic suppression was defined as HIV-1 RNA <=200 copies/mL at week 24, 48, and 72. The results obtained within +/- 12 weeks of 24, 48, and 72 weeks were included. If there were multiple HIV-1 RNA measurement within the specified window, the HIV-1 RNA result closest to the center of the window was selected.
At week 24, 48, 72
Self-management Skills, as Measured by Self-reported General Self-efficacy Scale (GSES) Score
Ramy czasowe: At weeks 0 (entry), 4, 12, 24, 36, 48, 60, and 72

The GSES is a 10-item scale designed to assess optimistic self-beliefs used to cope with a variety of demands in life. The scale was designed to assess self efficacy, i.e., the belief that one's actions are responsible for successful outcomes. The scaled score for each question ranges from 1 to 4. Higher scores indicate participant's stronger belief in self-efficacy.

The GSES score was sum of all responses. The range was from 0 to 40 scores: any unfinished question got a score of zero.
At weeks 0 (entry), 4, 12, 24, 36, 48, 60, and 72
Cumulative Probability of First Grade 3 or 4 Adverse Events (AEs)
Ramy czasowe: From study entry to week 72

The Kaplan-Meier estimate of the cumulative probability of experiencing a grade 3 or 4 adverse event by week 72.

New Grade 3 or 4 signs, symptoms were identified by MedDRA preferred term. Events were included regardless of participant status on ART. If a participant had multiple reports of the same event, only the event reported at the highest grade were included.

Time was measured from the study entry until the date of the first new grade 3 or 4 adverse event. Participants lost to follow-up prior to reaching an adverse event endpoint or not documented to have reached an adverse event endpoint at the end of the study had their endpoint censored at the date of their last visit.
From study entry to week 72

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

AIDS Clinical Trials Group

Współpracownicy

National Institute of Allergy and Infectious Diseases (NIAID)

Śledczy

  • Krzesło do nauki: Constance Benson, MD, University of California, San Diego
  • Krzesło do nauki: Tari Gilbert, MSN, University of California, San Diego

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 stycznia 2010

Zakończenie podstawowe (Rzeczywisty)

1 stycznia 2015

Ukończenie studiów (Rzeczywisty)

1 stycznia 2015

Daty rejestracji na studia

Pierwszy przesłany

7 października 2009

Pierwszy przesłany, który spełnia kryteria kontroli jakości

7 października 2009

Pierwszy wysłany (Oszacować)

8 października 2009

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

20 marca 2018

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

21 lutego 2018

Ostatnia weryfikacja

1 lutego 2018

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • ACTG A5250
  • 1U01AI068636 (Grant/umowa NIH USA)
  • 10654

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Zakażenia wirusem HIV

Badania kliniczne na CAP-IT

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Congo, DR of

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

3
Subskrybuj